Evidence map›Paper›PMID 39781720›Full record

SynthesisCurrent vascular pharmacology2025

Prognostic Value of Serum TMAO Measurement in Patients with STEMI: A Systematic Literature Review.

Georgios Vakadaris, Theofanis Korovesis, Charalampos Balomenakis, Andreas S Papazoglou, Stavros P Papadakos, Ioannis Karniadakis, Dimitrios V Moysidis, Konstantinos Arvanitakis, Georgios Germanidis, Emmanouil S Brilakis and 1 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Current vascular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Georgios VakadarisDivision of Gastroenterology and Hepatology, First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.
Theofanis KorovesisCardiology Department, Athens Naval Hospital, Athens, Greece.
Charalampos BalomenakisGeneral Surgery Department, Ulster Hospital, South Eastern Health and Social Care Trust, Upper Newtownards Rd, Dundonald, Belfast BT16 1RH, Northern Ireland.
Andreas S PapazoglouCardiology Department, Athens Naval Hospital, Athens, Greece.
Stavros P PapadakosDepartment of Gastroenterology, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Ioannis KarniadakisDepartment of Gastroenterology, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Dimitrios V Moysidis424 General Military Hospital, Thessaloniki, Greece.
Konstantinos ArvanitakisDivision of Gastroenterology and Hepatology, First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.
Georgios GermanidisDivision of Gastroenterology and Hepatology, First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.
Emmanouil S BrilakisCenter for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern, Minneapolis, MN 55407, USA.
Anastasios MilkasCardiology Department, Athens Naval Hospital, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGut microbiota-derived metabolite Trimethylamine-N-oxide (TMAO) is increasingly recognized as a potential novel prognostic biomarker for cardiovascular disease. Our research work aimed to investigate the potential utility of TMAO measurement in patients with STelevation Myocardial Infarction (STEMI).

methodsWe performed a systematic literature search in PubMed from inception to the 1st of February 2024 to identify all studies examining the association between plasma TMAO levels and disease complexity or clinical outcomes in STEMI patients.

resultsA total of eight prospective cohort studies were included, encompassing a total of 2,378 STEMI patients. Three of the studies provided only in-hospital evidence (i.e., increased odds for more severe coronary artery disease, plaque rupture, and plaque healing in patients with increased TMAO levels). Four studies examined the long-term prognostic value of TMAO after 10-12 months of follow-up post-STEMI (i.e., increased risk of adverse cardiovascular events in patients with increased TMAO levels), while one study provided data for both in-hospital and mid-term prognosis, indicating that 4-months after STEMI patients with greater TMAO elevation had larger infarct size.

conclusionHigher TMAO levels were associated with a greater prevalence of high-risk coronary plaque characteristics and worse in-hospital and follow-up outcomes in STEMI patients. Further study is needed on whether modulating the diet-dependent TMAO levels could improve clinical outcomes in these patients. REGISTRATION NUMBER: [(OSF): https://doi.org/10.17605/OSF.IO/WNG8V].

Indexed as

Gastrointestinal MicrobiomeMethylaminesST Elevation Myocardial InfarctionAgedBiomarkersFemaleHumansMaleMiddle AgedPredictive Value of TestsPrognosisRisk AssessmentRisk FactorsTime FactorsBiomarkersMethylaminestrimethyloxaminebiomarkercardiovascular disease.microbiomerisk stratificationSTEMITMAO

Identifiers

PMID39781720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.